Novartis' Reinhardt chairmanship officially begins, as Vasella's era fades

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Novartis' Reinhardt chairmanship officially begins, as Vasella's era fades

Novartis ($NVS) brought Joerg Reinhardt officially into the chairman's seat this week, bidding final farewell to Daniel Vasella, who had held the position since 1999. The ratification of Vasella's successor is a clear indication by Novartis that it's trying to make some changes in the way its former chairman operated, overhauling some of the projects he held closely, including Vasella's effort to diversify the company beyond its risky pharma business. With Reinhardt's entrance, Novartis is cutting back on executive compensation and pivoting away from some key policies and strategies employed long-term under Vasella. Story

Novartis
Joerg Reinhardt officially takes the chairman's seat.


WuXi PharmaTech
Hua Mu will head the product development service and partership business unit.


CRO

> WuXi Pharma ($WX) appointed Hua Mu to be the head of its product development and partnership business units. Release

> Thirty-year industry veteran Jane Winter joined INC Research to lead its global consulting practice. Release

> PSI named Gabriele Schmoetzer as its head of regulatory affairs in Germany. Release

Biotech

> Biotec Services appointed Fiona Withey to be its new CEO. Release

> Scynexis named Dr. Carole Sable as the company's chief medical officer. Release

> Dr. Thomas Ulich joined InVivo Therapeutics ($NVIV) as its chief scientific officer. Release

> Alchemia brought Thomas Liquard to the helm as the company's CEO. Release

> Immunome brought on three new executives: Jane Hollingsworth as executive chair, Joan Lau as COO and Joel Sussman as CFO. Release

> Lee Schacter joined Clinipace Worldwide as its oncology medical director. Release

> NewLink Genetics ($NLNK) appointed Dr. Eugene Kennedy as its vice president for clinical and medical affairs. Release

> Arno Therapeutics has appointed Lawrence Kenyon chief financial officer. Release

> Tauriga Sciences ($TAUG) has appointed Stella Sung chairman and CEO. Release

> Numira Biosciences adds Heather Ramsay as scientific director and Gonzalo Castillo as scientific director of oncology. Release | Release

> Otonomy has appointed Robert Savel as chief technical officer. Release

> David Hayes joins NeuroSigma as chief administrative officer, general counsel and senior vice president. Release

> Robert Lippe is joining Alexza Pharmaceuticals ($ALXA) as executive vice president of operations and chief operations officer. Release

> Aerie Pharmaceuticals ($AERI) has named Marvin Garrett vice president of regulatory affairs and quality assurance. Release

> AMAG Pharmaceuticals ($AMAG) has appointed Edward Jordan senior vice president of sales and marketing. Release

Pharma

> Catabasis Pharmaceuticals appointed Andrew Nichols as its vice president of research. Release

> Jazz Pharmaceuticals ($JAZZ) brought on Kathryn Falberg as its executive vice president and CFO. Release

> Nuventra Pharma Sciences appoints Mark Bush as chief scientific officer. Release

Medical Devices

> Boston Therapeutics has appointed Larry Ellingson, former chair of the American Diabetes Association, as chair of its scientific advisory board. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.